Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2019 | New therapies in AML with Steven Knapper

Steven Knapper • 2 Apr 2019
BSH 2019
Acute Myeloid Leukemia Leukemia CPX-351 Cytarabine Daunorubicin Gemtuzumab ozogamicin Midostaurin
RATIFY

Steven Knapper, DM, FRCPath, MRCP, BMBCh, Cardiff University, Cardiff, Wales, UK, speaks at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK. He gives us an overview of new therapies in acute myeloid leukemia (AML), which has seen an explosion of new agents and approvals.

More from Steven Knapper

1:12
The value of FLT3 inhibitors in AML and focus for future trial designs
Steven Knapper • 24 Apr 2023
2:09
Advances in the management of fit adults with AML
Steven Knapper • 24 Apr 2023
2:22
Session highlights: IDH inhibitors, salvage regimens, and other novel developments in AML
Steven Knapper • 24 Apr 2023
3:59
The challenges of post-MPN AML
Steven Knapper • 15 Nov 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals